Industrial Purity N-(4-Methyl-1,3-Thiazol-2-Yl)Acetamide Coa 2026
- Assay Verification: Rigorous HPLC testing ensures purity levels consistently exceed 98% for critical synthetic applications.
- Documentation: Comprehensive Certificate of Analysis (COA) provided for every batch to meet regulatory compliance.
- Scalability: Optimized manufacturing processes support seamless transition from R&D to industrial scale-up.
In the realm of pharmaceutical process development, the reliability of key building blocks determines the success of the final active pharmaceutical ingredient (API). N-(4-methyl-1,3-thiazol-2-yl)acetamide (CAS: 7336-51-8) stands as a critical chemical intermediate utilized in the synthesis of various bioactive compounds. As regulatory requirements tighten and production scales increase, the demand for verifiable industrial purity has never been higher. Procurement teams must prioritize suppliers who offer transparent quality assurance and consistent batch-to-batch reproducibility.
At NINGBO INNO PHARMCHEM CO.,LTD., we understand that minor impurities in thiazole derivatives can significantly impact downstream reaction yields and catalyst performance. This technical overview details the synthesis standards, quality control protocols, and supply chain capabilities required to secure high-grade materials for 2026 production cycles.
Verifying Assay Levels Above 98 Percent
The structural integrity of thiazole-based intermediates is paramount. Standard commercial grades often hover around 95% purity, which may suffice for early-stage discovery but poses risks during process validation. For industrial applications, achieving an assay level above 98% is the benchmark for minimizing side reactions and simplifying purification workflows.
Our quality control laboratories utilize high-performance liquid chromatography (HPLC) coupled with mass spectrometry to quantify the main component and identify related substances. The molecular formula C6H8N2OS represents a specific stoichiometry that must be maintained. Deviations often indicate incomplete acetylation or the presence of unreacted amine precursors. By enforcing strict acceptance criteria, we ensure that the synthesis route employed yields a product free from problematic isomers or residual solvents that could interfere with subsequent coupling reactions.
When sourcing high-purity N-(4-Methylthiazol-2-yl)acetamide, buyers should request detailed chromatograms alongside the certificate of analysis. This data provides visibility into the impurity profile, allowing process chemists to assess compatibility with sensitive catalytic systems. Consistency in assay levels reduces the need for additional recrystallization steps, thereby improving overall process economics.
Certificate of Analysis Documentation Standards
In a regulated environment, documentation is as valuable as the physical product. A robust COA serves as the legal and technical guarantee of quality. It must extend beyond simple identity confirmation to include quantitative data on purity, moisture content, and residual solvents. For a global manufacturer serving diverse markets, adherence to international pharmacopoeia standards is non-negotiable.
Key parameters typically verified in our documentation include:
- Identification: Confirmed via IR and NMR spectroscopy to match the reference standard.
- Purity: Determined by area normalization methods in HPLC, targeting >98.0%.
- Loss on Drying: Ensures stability during storage and transport.
- Residual Solvents: Screened against ICH Q3C guidelines to ensure safety.
Transparency in documentation facilitates faster regulatory filings and reduces audit friction. Clients partnering with NINGBO INNO PHARMCHEM CO.,LTD. receive digital and physical copies of batch-specific records, ensuring full traceability from raw material intake to final dispatch. This level of detail is essential for maintaining the chain of custody required in modern pharmaceutical supply chains.
Batch Consistency for Industrial Scale Up
Transitioning from gram-scale laboratory synthesis to multi-ton production introduces variability challenges. A reliable manufacturing process must demonstrate robustness against minor fluctuations in temperature, pressure, and reagent quality. Batch consistency is the metric that defines a supplier's capability to support long-term commercial production.
Our facility employs continuous improvement methodologies to optimize the acetylation of the thiazole amine precursor. By controlling reaction kinetics and crystallization parameters, we minimize particle size distribution variations, which can affect flowability and dissolution rates in downstream processing. This stability is crucial for 4-Methylthiazole-2-acetamide users who rely on automated dosing systems.
Technical Specifications Overview
The following table outlines the standard technical specifications maintained for industrial supply. These parameters are designed to meet the rigorous demands of organic synthesis and process chemistry.
| Parameter | Specification | Test Method |
|---|---|---|
| Product Name | N-(4-Methyl-1,3-Thiazol-2-Yl)Acetamide | - |
| CAS Number | 7336-51-8 | - |
| Molecular Formula | C6H8N2OS | - |
| Molecular Weight | 156.21 g/mol | - |
| Appearance | White to Off-White Crystalline Powder | Visual |
| Purity (HPLC) | > 98.0% | Area Normalization |
| Loss on Drying | < 0.5% | Karl Fischer / LOD |
| Storage Conditions | Store in a cool, dry place (Room Temperature) | - |
Strategic Procurement and Bulk Pricing
Securing a stable supply chain for critical intermediates requires a partnership model rather than a transactional approach. Bulk price stability is influenced by raw material availability and energy costs, but long-term agreements can mitigate market volatility. Factory supply direct from the manufacturer eliminates intermediary markups and reduces lead times.
For organizations planning production runs into 2026 and beyond, locking in quality assurance protocols early is advisable. Our logistics network supports global distribution with compliant packaging that ensures product integrity during transit. Whether the requirement is for pilot plant trials or full-scale commercial manufacturing, the focus remains on delivering organic synthesis ready materials that perform predictably.
In conclusion, the selection of a thiazole derivative supplier should be driven by data, transparency, and scalability. By prioritizing industrial purity and comprehensive documentation, pharmaceutical manufacturers can safeguard their production timelines and maintain the highest standards of product quality.